期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

荧光原位杂交技术对多发性骨髓瘤染色体异常的检测及意义 被引量：4

下载PDF
导出
摘要 荧光原位杂交技术是分子遗传学中的一项重要技术,对染色体异常疾病的检测,比常规细胞遗传学方法更具优势。在多发性骨髓瘤染色体异常检测中的意义,不仅体现在其高效的检出灵敏度和特异性上,在微小残留病变的检测上也很有价值。荧光原位杂交技术有利于多发性骨髓瘤发病机制的研究,对其开发新疗法,提高治愈率具有重要意义。
作者 刘静芸 林婴 杨季云
机构地区 重庆医科大学医学检验系 四川省医学科学院.四川省人民医院人类疾病基因研究四川省重点实验室
出处 《国际检验医学杂志》 CAS 2009年第4期349-350,352,共3页 International Journal of Laboratory Medicine
基金 卫生部科研基金课题(WKJ2007-3-001)
关键词 原位杂交 荧光 多发性骨髓瘤 染色体畸变
分类号 R730.43 [医药卫生—肿瘤] R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Debes Marun CS, Dewald GW, Bryant S, et al. Chromosome ab normalities clustering and its implications for pathogenesis and prognosis in myeloma[J]. Leukemia, 2003,17 (2) : 427-436.
  • 2Harrison CJ, Mazzullo H, Cheung KL, et al. Cytogenetics of multi pie myeloma: interpretation of fluorescence in situ hybridization results[J]. Br J Haematol,2003,120(6) :944-952.
  • 3张艳,江滨,黄晓军,师岩,何琦,党辉,邱镜滢,陆道培.多发性骨髓瘤的细胞遗传学研究[J].中国实验血液学杂志,2007,15(1):76-78. 被引量：20
  • 4李建勇,潘金兰,葛峥,沈云峰,仇海荣,吴冠宇,吴亚芳,肖冰,薛永权.间期荧光原位杂交技术检测多发性骨髓瘤3号染色体三体[J].临床检验杂志,2006,24(1):56-57. 被引量：4
  • 5Smadja NV, Leroux D, Soulier J, et al. Further cytogenetie charac terization of multiple myeloma confirms that 14q32 transloeations are a very rare event in hyperdiploid eases[J]. Genes Chromosomes Cancer,2003,38(3):234-239.
  • 6Chang H,Sloan S,Li D,et al. The t(4,14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant[J].Br J Haematol, 2004,125 (1) : 64-68.
  • 7Chang H,Sloan S,Li D,et al. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.,1 (p53) deletions[J]. Br J Haematol, 2004,127(3) : 280-284.
  • 8吴文,沈志祥.2006血液病学新进展[M].北京:人民卫生出版社,2006.173-188.
  • 9Sawyer JR. Multicolor spectral karyotyping in multiple myeloma [J].Methods Mol Med, 2005,113:49-58.
  • 10Pantou D,Rizou H ,Tsarouha H, et al. Cytogenetic manifestations of multiple myeloma heterogeneity[J].Genes Chromosomes Cancer,2005,42(1) :44 -57.

二级参考文献17

  • 1张之南.血液病诊断与疗效标准[M].北京:科学技术出版社,1998.304.
  • 2[1]Calasanz M J,Cigudosa J C,Odero M D,et al.Cytogenetics analysis of 280 patients with multiple myeloma and related disorder:primary breakpoints and clinical correlations[J].Genes Chromosom Cancer,1997,18(2):84-93.
  • 3[2]Seong C,Delasalle K,Hayes K,et al.Prognostic value of cytogenetics in multiple myeloma[J].Br J Haematol,1998,101 (1):189-194.
  • 4[3]Dubinsky R,Amiel A,Manor Y,et al.Fluorescence in situ hybridization (FISH) for retrospective detection of trisomies 3 and 7 in multiple myeloma[J].Cancer Genet C ytogenet,1995,83 (2):115-118.
  • 5[6]Mitelman F.Aninternational system for human cytogenetic nomenclature[M].Basel:Karger S,1995.
  • 6[8]Drach J,Schuster J,Nowotny H,et al.Multiple myeloma:High incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization[J].Cancer Res,1995,55 (17):3854-3859.
  • 7[9]Perez-Simon J A,Garcia-Sanz R,Tabernero M D,et al.Prognostic value of numerical chromosome aberrations in multiple myeloma:a FISH analysis of 15 different chromosomes[J].Blood,1998,91 (9):3366-3371.
  • 8Debes-Marum CS, Dewald GW, Bryant S, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia, 2003 ; 17:427 - 436
  • 9Lai JL, Zandecki M, Mary JY, et al. Improved cytogenetics in multiple myeloma:a study of 151 patients including 117 patients at diagnosis. Blood, 1995 ; 85:2490 - 2497
  • 10Harrison C J, Mazzullo H, Cheung KL, et al. Cytogenetics of multiple myeloma:interpretation of fluorescence in situ hybridization resuits. Br J Haematol, 2003; 120:944 -952

共引文献22

同被引文献30

  • 1<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量：164
  • 2邓明凤,王昌富,吴刚珂,陈永玲,唐全.急性白血病、慢性髓细胞白血病及骨髓增生异常综合征患者染色体分析[J].中国优生与遗传杂志,2007,15(2):45-46. 被引量：2
  • 3Ross JS, Gray GS. Targeted therapy for cancer: the HER-2/neu and Herceptin story[J]. Clin Leadersh Manag Rev, 2003,17 (6) : 333-340.
  • 4Powell WC, Hicks DG,Prescott N, et al. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determina- tion of the HER2 status in breast cancer:comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory re- producibility[J]. Appl Immunohistochem Mol Morphol, 2007,15 (1) :94-102.
  • 5Roche PC,Surnan VJ,Jebkins RB, et al. Concordance between locat and central laboratory HER2 testing in the breast intergroup trial N9381[J]. J Natl Cancer Inst,2002,94(11):855-857.
  • 6Moeder CB,Gilmane JM, Harigopal M, et al. Quantitative justifi cation of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clini- cal Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue mi croarray based assessment of outcome[J]. J Clin Oncol, 2007,25 (34) :5418 5425.
  • 7Hsu CY. Ho DM. Yang CF,et al. Interobserver reproducibility of HER-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest[J]. Am J Clin Patbol, 2002, 118 (5) :693-698.
  • 8Santinelli A, Baccarini M, Colanzi P, et al. Immunohistochemical evaluation of HER2/neu expression in infiltrating breast cancino ma : a study of reproducibility[J]. Anal Quant Cytol Histol, 2002, 24(1) ,54-62,.
  • 9Wolff AC, Hammond ME, Schwartz J N, et al. American Society of Clinical Oncology/College of American Pathologists guideline rec ommendations for human epidermal growth factor receptor 2 tes- ting in breast cancer[J ]. J Clin Oncol, 2 0 0 7,2 5 ( 1 ): 118-14 5.
  • 10Dowsett M,Hanby AM,I.aing R,et al. HER2 testing in the UK: consensus from a national consultation[J]. J Clin Pathol, 2007,60 (6) :685-689.

引证文献4

二级引证文献6

国际检验医学杂志
2009年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部